And so, another working week will soon draw to a close. Not a moment too soon, yes? After all, it has been a busy few days. This is, you may recall, our treasured signal to daydream about weekend plans. As usual, our agenda is rather modest. We hope to catch up on some reading and napping, promenade with the official mascots, and enjoy time with the Pharmalot phamily. And what about you? The election is nearing, which means you can start placing your bets. You can enjoy the great outdoors as the cool and delightful autumn season unfolds. Or you can simply plan the rest of your life. Well, whatever you do, have a grand time, but be safe. Enjoy and see you soon …
Some of the parent bloggers who were recruited by Mylan to promote the use of the EpiPen in schools believe the company took advantage of their goodwill with price hikes, Reuters reports. The drug maker sponsored at least four summits, each involving about 15 bloggers, some of whom attended more than one event. And they wrote about being treated to three-course dinners featuring pan-seared yellowfin tuna or marinated grilled hanger steak.
The US Food and Drug Administration issued a warning about a do-it-yourself version of the EpiPen called the EpiPencil, US News & World Report writes. An instructional video provides links to buy parts needed to assemble an auto-injector at home, and it is estimated to cost just $30. “The idea is that someone can do what we’ve done,” said Michael Lauder, a mathematics lecturer at Menlo College.
At least 30 percent of investors have voted against the Mylan Pharmaceuticals executive pay program in every vote on the matter since 2011, Bloomberg News informs us. The drug maker maintains there is “strong support” for its program, but experts disagree. “I don’t know of any company that considers approval in the 60 percent range to be strong support,” said Robin Ferracone, who heads Farient Advisors, an executive compensation consulting firm.
The UK’s National Institute for Health and Care Excellence wants Alexion Pharmaceuticals to find more ways to lower the cost of its new Strensiq drug to treat a rare inherited bone disorder, Reuters reports. The treatment could cost up to $2 million a year per patient has been cleared for limited use, but the cost watchdog, which initially rejected the drug as too expensive, wants Alexion to offer something more than a discount to cap the price.
Endo Pharmaceutical chief executive Rajiv De Silva stepped down and also left the board, a year after the drug maker completed its acquisition of Par Pharmaceuticals. The company named Paul Campanelli as its new chief executive, effective immediately. Campanelli had headed Par, but then became president of Endo’s generic and over-the-counter business after the deal closed.
Bayer’s failure to identify weaknesses in Merck’s over-the-counter drug business before it bought it in 2014 raises questions about the vetting that Bayer has done on its $14.2 billion Monsanto deal, the Wall Street Journal says.
A drug that Lundbeck is developing to treat Alzheimer’s failed to meet its objectives in the first of three late-stage trials, according to PMLive.
The UK’s NICE has recommended Epclusa, the latest hepatitis C treatment from Gilead Sciences, for coverage, Pharmaphorum says.
A Novartis drug called Zykadia outperformed chemotherapy in patients with a rare form of lung cancer, but faces competition from a Roche medicine that some analysts say may already have the upper hand, Reuters writes.
European regulators endorsed an Allergan drug called Truberzi, giving patients potential access to the first approved treatment for irritable bowel syndrome with diarrhea, PharmaTimes tells us.